Unavailable
Unavailable
Save time and jump to the most important pieces.
10-Q - NanoVibronix, Inc. (0001326706) (Filer)
SCHEDULE 13G - NanoVibronix, Inc. (0001326706) (Subject)
8-K - NanoVibronix, Inc. (0001326706) (Filer)
NanoVibronix, Inc. (the "Company") (NASDAQ:NAOV) confirmed that a series of posts made earlier today with respect to a $26 million registered direct offering of common stock of the Company priced at $0.45 under Nasdaq rules was falsely issued by Flash Alert and FintelAlerts. The Company has not priced and is not consummating any registered direct offering. The Company is actively investigating this misinformation and will take necessary actions to protect its stockholders and its reputation. View source version on businesswire.com: https://www.businesswire.com/news/home/20250528125762/en/ Brett Maas, Managing Principal Hayden IR, LLC [email protected] (646) 536-7331
Greater New Orleans Area Facility to Transition from Blind Insertions to FDA-Cleared Electromagnetic Guidance NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division ("ENvue Medical"), that a major 420-bed acute care hospital located in the greater New Orleans area has selected the ENvue™ Navigation Platform (the "ENvue System") to support adult feeding tube procedures. The hospital will transition from traditional blind insertions to real-time, electromagnetic-guided placement using the ENvue System. The ENvue System is FDA-cleared for nasoenter
NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the closing of its previously announced underwritten public offering of 400,000 shares of the Company's Series G Convertible Preferred Stock ("Preferred Stock"), with a par value $0.001 per share and a stated value equal to $25, and Warrants to purchase up to 4,901,982 shares of common stock, par value $0.001 per share (the "Common Stock") of the Company at an exercise price of $2.04 per share (the "Warrants"). The combined public offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00. The Warrants have
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G - NanoVibronix, Inc. (0001326706) (Subject)
SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)
NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
4 - NanoVibronix, Inc. (0001326706) (Issuer)
NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on
Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr
MONTREAL, April 29, 2022 /CNW Telbec/ - Cerro de Pasco Resources Inc. (CSE:CDPR) (Frankfurt: N8HP) ("CDPR" or the "Company") announces that it has applied to the Autorité des marchés financiers (Québec) (the "AMF"), as principal regulator of the Company, and expects to be granted a management cease trade order (the "MCTO") on May 2, 2022, pursuant to Policy Statement 12-203 Respecting Management Cease Trade Orders ("PS 12-203"). Under the MCTO, the Company's Chief Executive Officer (CEO), Chief Financial Officer (CFO) and directors may not trade in securities of the Company until such time as the Company files its audited consolidated financial statements, its management's discussion and ana